Latest Research And Development News

Biotron Limited has closed its non-renounceable rights issue, raising $645,861 to advance its Hepatitis B virus drug development, with a shortfall commitment from Peak Asset Management still pending.

Bass Oil reported a 2% rise in November oil production alongside a new gas sales agreement with Origin Energy, setting the stage for first gas sales in 2026. Indonesian operations also advanced with production enhancements and upcoming drilling plans.

Sparc Technologies has achieved a significant commercial milestone with its first sale of ecosparc®, a graphene-based additive for protective coatings, to an Asian coatings company following successful proof-of-concept testing.

Truscott Mining Corporation has initiated a $1.44 million capital raise through a share placement accompanied by unlisted options, aiming to bolster its exploration and development efforts.

Epiminder Limited has settled a $15.77 million tax liability with the ATO related to historical R&D claims, freeing up $4.23 million from IPO proceeds for working capital.

DataWorks Group signals a turning point with its strongest quarterly operating cash flow since refocusing on its core RegTech business, driven by key contracts in Australia and Ontario.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Dimerix has successfully completed recruitment and dosing of 286 adult patients in its Phase 3 ACTION3 trial evaluating DMX-200 for focal segmental glomerulosclerosis (FSGS), advancing toward regulatory discussions with the FDA.

Swift TV Ltd has locked in pre-sales with five aged care providers, activating 1,246 screens ahead of its official launch and setting the stage for subscription revenue by March 2026.

Pilot Energy has secured a $1.52 million financing facility to fast-track its FY2025 R&D Tax Incentive refund, supporting its clean energy and gas exploration projects.

EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.

Immuron Limited reports topline results from a Uniformed Services University trial of a third-party ETEC product that missed its primary endpoint, reaffirming commitment to its established Travelan dosing ahead of FDA discussions.